Global Industry Analyst | 380 pages | October 2005 | English
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in Millions of US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pa ...
IntroductionUntil a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. ...
Datamonitor's Generics in Belgium industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation ...
IntroductionThe oncology market has shown remarkable growth in recent years, driven by the advent of targeted therapy and the high level of unmet needs in the disease, and it is poised for further exp ...
IntroductionVicals main focus is to research and develop vaccines and novel therapeutics based on its core DNA delivery technology for the treatment of wide range of diseases in the areas of infectio ...
India has emerged as a strong base for clinical trials in recent times. Due to the multitude of benefits it offers, the country is fast growing as a centre for conducting clinical trials for many i ...
Datamonitor's Nastech Pharmaceutical Company Inc - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the companys key business s ...
The metrics in this report cover three year trends in Tinctures, pharmaceutical [Manufacturing sector], broken out on a state-by-state basis. Analysis is based on data applied from 1 industry firms ...
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives. It provides monthly insight into the key events in the cancer therapeutic area. MarketWatch features all the ...
Cygnus Business Consulting & Research | 82 pages | May 2006 | English
The global pharmaceutical industry is at the cross roads. With many of the blockbuster drugs getting off-patented and with increasing R&D costs, it's hard by the companies to maintain their bottom- ...
